Selangor Journal
The health supplement ‘Beni Koji Choleste Help’, which contains red yeast rice (RYR) and is manufactured by Japan’s Kobayashi Pharmaceutical Co., has been linked to at least four deaths in Japan starting on March 27, 2024, and which has triggered a recall of the product. — Picture via X/@ShanghaiEye

‘Beni Koji Choleste Help’ supplement unregistered in Malaysia — Health Ministry

PUTRAJAYA, April 1 — The Health Ministry (MOH) has confirmed the health supplement ‘Beni Koji Choleste Help’, which contains red yeast rice (RYR) and is manufactured by Japan’s Kobayashi Pharmaceutical Co., is not registered in Malaysia.

National Pharmaceutical Regulatory Agency (NPRA) director Rosilawati Ahmad said this was confirmed after a comprehensive review of its registered product database.

“The review also revealed over a hundred other products containing RYR, manufactured by various companies, which have been registered in Malaysia,” she said in a statement today.

RYR is derived from the fermentation process of rice using a specific yeast strain called Monascus purpureus.

During this fermentation process, the predominant natural components are monacolins, with Monacolin-K being the most prominent.

Monacolin-K’s chemical structure is identical to that of lovastatin, a widely prescribed medication for managing blood cholesterol levels.

Consequently, Rosilawati said products containing RYR (Monascus purpureus) must undergo registration with the Drug Control Authority (DCA) under either the traditional products or health supplements category.

The DCA has established limits for Monacolin-K in finished products, stipulating that it should not exceed one per cent and the daily intake of Monacolin-K should not surpass 10mg daily.

“The company is required to provide laboratory analysis certificates for the Monacolin-K content in both finished products and raw materials containing RYR,” she said.

All registered products containing RYR must comply with precise labelling criteria as outlined in the NPRA’s Drug Registration Guidance Document (DRGD).

This entails providing statements to inform consumers that the product contains naturally occurring lovastatin, along with potential side effects like body and muscle pain, as well as fatigue resulting from product consumption.

Rosilawati urged the public to only consume registered health products, which undergo safety and quality evaluations prior to approval.

“MOH, via NPRA, consistently monitors registered products to ensure their safety and high quality for consumers,” she said.

Local and international media have earlier reported on the recall of these health supplement products, which were linked with reported deaths among consumers overseas.

— Bernama

 

Top Picks

MCMC rejects allegations made by blogger, lodges police report

UTAR student sole Chinese candidate to complete Pulpak basic commando course

Border strife: Malaysia-Thailand routes in Kelantan temporarily closed